Original paper
LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
Abstract
Patients with advanced hepatocellular carcinoma (aHCC) not amenable to surgical resection or locoregional therapy may be treated with multitargeted kinase inhibitors or immuno-oncology–based combination therapy. Sorafenib is approved as first-line (1L) therapy but provides only a modest survival benefit. Despite approved 1L therapies for aHCC, there remains an unmet need to prolong survival while improving treatment tolerability. The phase 3...
Paper Details
Title
LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
Published Date
Jul 1, 2020
Journal
Volume
31
Pages
S241 - S242
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History